Arachnoiditis Market Research Report Information by Type (Adhesive Arachnoiditis and Others), Cause (Chemically induced and Others), Diagnosis (Computerized Axial Tomography), Treatment (Physical Therapy), End User (Hospitals & Clinics) - Forecast till 2032

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Arachnoiditis Market, by Type

6.1 Introduction

6.2 Adhesive Arachnoiditis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Cerebral Arachnoiditis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Arachnoiditis Ossificans

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5 Hereditary Arachnoiditis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6 Neoplastic Arachnoiditis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.7 Optochiasmatic Arachnoiditis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Arachnoiditis Market, by Cause

7.1 Introduction

7.2 Trauma/Surgery Induced

7.2.1 Spinal Surgery

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.2 Lumbar Puncture

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.3 Spinal Stenosis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.2.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Chemically Induced

7.3.1 Myelograms

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3.1 Epidural Steroid Injection

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Infection Induced

7.4.1 Viral and Fungal Meningitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4.2 Tuberculosis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Arachnoiditis Market, by Diagnosis

8.1 Introduction

8.2 CAT Scan (Computerized Axial Tomography)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 MRI (Magnetic Resonance Imaging)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Electromyogram (EMG)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Arachnoiditis Market, by Treatment

9.1 Introduction

9.2 Physical Therapy

9.2.1 Hydrotherapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.2.2 Massage

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.2.3 Hot/Cold Therapy

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3 Pain Medications

9.3.1 Lidocaine Intravenous (IV) Infusion

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3.2 Ketamine IV Infusions

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3.4 Naltrexone

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4 Nerve Stimulation

9.4.1 Spinal Cord Stimulation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4.2 Transcutaneous Electrical Nerve Stimulation (TENS)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.5 Psychological Support

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 10. Global Arachnoiditis Market, by End-User

10.1 Introduction

10.2 Hospital and Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10.3 Pharmacies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10.4 Diagnostic Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10.5 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 11. Global Arachnoiditis Market, by Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 US

11.2.1.2 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 Italy

11.3.1.4 Spain

11.3.1.5 UK

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia-Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 South Korea

11.4.6 Rest of Asia-Pacific

11.5 Middle East & Africa

11.5.1 Middle East

11.5.2 Africa

Chapter 12. Company Landscape

12.1 Introduction

12.2 Market Share Analysis

12.3 Key Development & Strategies

Chapter 13. Company Profiles

13.1 Baxter

13.1.1 Company Overview

13.1.2 Product Overview

13.1.3 Financials Overview

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.2 B. Braun Melsungen AG

13.2.1 Company Overview

13.2.2 Product Overview

13.2.3 Financial Overview

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.3 Pfizer Inc.

13.3.1 Company Overview

13.3.2 Product Overview

13.3.3 Financial Overview

13.3.4 Key Development

13.3.5 SWOT Analysis

13.4 SR Pharma

13.4.1 Company Overview

13.4.2 Technology/Business Segment Overview

13.4.3 Financial Overview

13.4.4 Key Development

13.4.5 SWOT Analysis

13.5 SR Pharma

13.5.1 Company Overview

13.5.2 Product Overview

13.5.3 Financial overview

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.6 Abbott

13.6.1 Company Overview

13.6.2 Product Overview

13.6.3 Financial Overview

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.7 AstraZeneca

13.7.1 Overview

13.7.2 Product Overview

13.7.3 Financial Overview

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.8 Bristol-Myers Squibb Company

13.8.1 Overview

13.8.2 Product/Technology Overview

13.8.3 Financials

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.9 Sandoz International GmbH

13.9.1 Overview

13.9.2 Product Overview

13.9.3 Financials

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.10 DuPont

13.10.1 Overview

13.10.2 Product Overview

13.10.3 Financials

13.10.4 Key Developments

13.10.5 SWOT Analysis

13.11 Takeda Pharmaceutical Company Limited

13.11.1 Overview

13.11.2 Product Overview

13.11.3 Financials

13.11.4 Key Developments

13.11.5 SWOT Analysis

13.12 Novartis AG

13.12.1 Overview

13.12.2 Product Overview

13.12.3 Financials

13.12.4 Key Developments

13.12.5 SWOT Analysis

Chapter 14 MRFR Conclusion

14.1 Key Findings

14.1.1 From CEO’s Viewpoint

14.1.2 Unmet Needs of the Market

14.2 Key Companies to Watch

14.3 Predictions for the Arachnoiditis Industry

Chapter 15. Appendix

LIST OF TABLES

Table 1 Global Arachnoiditis Market Synopsis, 2020-2027

Table 2 Global Arachnoiditis Market Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Arachnoiditis Market, by Region, 2020-2027 (USD Million)

Table 4 Global Arachnoiditis Market, by Type, 2020-2027 (USD Million)

Table 5 Global Arachnoiditis Market, by Cause, 2020-2027 (USD Million)

Table 6 Global Arachnoiditis Market, by Diagnosis, 2020-2027 (USD Million)\

Table 7 Global Arachnoiditis Market, by Treatment, 2020-2027 (USD Million)

Table 8 Global Arachnoiditis Market, by End-User, 2020-2027 (USD Million)

Table 9 North America: Arachnoiditis Market, by Type, 2020-2027 (USD

Million)

Table 10 North America: Arachnoiditis Market, by Cause, 2020-2027 (USD

Million)

Table 11 North America: Arachnoiditis Market, by Diagnosis, 2020-2027 (USD

Million)

Table 12 North America: Arachnoiditis Market, by Treatment, 2020-2027 (USD

Million)

Table 13 North America: Arachnoiditis Market, by End-User, 2020-2027 (USD

Million)

Table 14 US: Arachnoiditis Market, by Type, 2020-2027 (USD Million)

Table 15 US: Arachnoiditis Market, by Cause, 2020-2027 (USD Million)

Table 16 US: Arachnoiditis Market, by Diagnosis, 2020-2027 (USD Million)

Table 17 US: Arachnoiditis Market, by Treatment, 2020-2027 (USD Million)

Table 18 US: Arachnoiditis Market, by End-User, 2020-2027 (USD Million)

Table 19 Canada: Arachnoiditis Market, by Type, 2020-2027 (USD Million)

Table 20 Canada: Arachnoiditis Market, by Cause, 2020-2027 (USD Million)

Table 21 Canada: Arachnoiditis Market, by Diagnosis, 2020-2027 (USD Million)

Table 22 Canada: Arachnoiditis Market, by Treatment, 2020-2027 (USD

Million)

Table 23 Canada: Arachnoiditis Market, by End-User, 2020-2027 (USD

Million)

Table 24 South America: Arachnoiditis Market, by Type, 2020-2027 (USD

Million)

Table 25 South America: Arachnoiditis Market, by Cause, 2020-2027 (USD

Million)

Table 26 South America: Arachnoiditis Market, by Diagnosis, 2020-2027 (USD

Million)

Table 27 South America: Arachnoiditis Market, by Treatment, 2020-2027 (USD

Million)

Table 28 South America: Arachnoiditis Market, by End-User, 2020-2027 (USD

Million)

Table 29 Europe: Arachnoiditis Market, by Type, 2020-2027 (USD Million)

Table 30 Europe: Arachnoiditis Market, by Cause, 2020-2027 (USD Million)

Table 31 Europe: Arachnoiditis Market, by Diagnosis, 2020-2027 (USD Million)

Table 32 Europe: Arachnoiditis Market, by Treatment, 2020-2027 (USD Million)

Table 33 Europe: Arachnoiditis Market, by End-User, 2020-2027 (USD Million)

Table 34 Western Europe: Arachnoiditis Market, by Type, 2020-2027 (USD

Million)

Table 35 Western Europe: Arachnoiditis Market, by Cause, 2020-2027 (USD

Million)

Table 36 Western Europe: Arachnoiditis Market, by Diagnosis, 2020-2027 (USD

Million)

Table 37 Western Europe: Arachnoiditis Market, by Treatment, 2020-2027

(USD Million)

Table 38 Western Europe: Arachnoiditis Market, by End-User, 2020-2027

(USD Million)

Table 39 Eastern Europe: Arachnoiditis Market, by Type, 2020-2027 (USD

Million)

Table 40 Eastern Europe: Arachnoiditis Market, by Cause, 2020-2027 (USD

Million)

Table 41 Eastern Europe: Arachnoiditis Market, by Diagnosis, 2020-2027 (USD

Million)

Table 42 Eastern Europe: Arachnoiditis Market, by Treatment, 2020-2027

(USD Million)

Table 43 Eastern Europe: Arachnoiditis Market, by End-User, 2020-2027

(USD Million)

Table 44 Asia-Pacific: Arachnoiditis Market, by Type, 2020-2027 (USD

Million)

Table 45 Asia-Pacific: Arachnoiditis Market, by Cause, 2020-2027 (USD

Million)

Table 46 Asia-Pacific: Arachnoiditis Market, by Diagnosis, 2020-2027 (USD

Million)

Table 47 Asia-Pacific: Arachnoiditis Market, by Treatment, 2020-2027 (USD

Million)

Table 48 Asia-Pacific: Arachnoiditis Market, by End-User, 2020-2027 (USD

Million)

Table 49 Middle East & Africa: Arachnoiditis Market, by Type, 2020-2027

(USD Million)

Table 50 Middle East & Africa: Arachnoiditis Market, by Cause, 2020-2027

(USD Million)

Table 51 Middle East & Africa: Arachnoiditis Market, by Diagnosis, 2020-2027

(USD Million)

Table 52 Middle East & Africa: Arachnoiditis Market, by Treatment, 2020-2027

(USD Million)

Table 53 Middle East & Africa: Arachnoiditis Market, by End-User, 2020-2027

(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Arachnoiditis Market

Figure 3 Segmentation Market Dynamics for Global Arachnoiditis Market

Figure 4 Global Arachnoiditis Market Share, by Type, 2020

Figure 5 Global Arachnoiditis Market Share, by Cause, 2020

Figure 6 Global Arachnoiditis Market Share, by Diagnosis, 2020

Figure 7 Global Arachnoiditis Market Share, by Treatment, 2020

Figure 8 Global Arachnoiditis Market Share, by End-User, 2020

Figure 9 Global Arachnoiditis Market Share, by Region, 2020

Figure 10 North America: Arachnoiditis Market Share, by Country, 2020

Figure 11 Europe: Arachnoiditis Market Share, by Country, 2020

Figure 12 Asia-Pacific: Arachnoiditis Market Share, by Country, 2020

Figure 13 Middle East & Africa: Arachnoiditis Market Share, by Country, 2020

Figure 14 Global Arachnoiditis Market: Company Share Analysis, 2020 (%)

Figure 15 Baxter: Key Financials

Figure 16 Baxter: Segmental Revenue

Figure 17 Baxter: Geographical Revenue

Figure 18 B. Braun Melsungen AG: Key Financials

Figure 19 B. Braun Melsungen AG: Segmental Revenue

Figure 20 B. Braun Melsungen AG: Geographical Revenue

Figure 21 Pfizer Inc.: Key Financials

Figure 22 Pfizer Inc.: Segmental Revenue

Figure 23 Pfizer Inc.: Geographical Revenue

Figure 24 SR Pharma: Key Financials

Figure 25 SR Pharma: Segmental Revenue

Figure 26 SR Pharma: Geographical Revenue

Figure 27 SR Pharma: Key Financials

Figure 28 SR Pharma: Segmental Revenue

Figure 29 SR Pharma. Geographical Revenue

Figure 30 Abbott: Key Financials

Figure 31 Abbott: Segmental Revenue

Figure 32 Abbott: Geographical Revenue

Figure 33 AstraZeneca: Key Financials

Figure 34 AstraZeneca: Segmental Revenue

Figure 35 AstraZeneca: Geographical Revenue

Figure 36 Bristol-Myers Squibb Company: Key Financials

Figure 37 Bristol-Myers Squibb Company: Segmental Revenue

Figure 38 Bristol-Myers Squibb Company: Geographical Revenue

Figure 39 Sandoz International GmbH: Key Financials

Figure 40 Sandoz International GmbH: Segmental Revenue

Figure 41 Sandoz International GmbH: Geographical Revenue

Figure 42 DuPont: Key Financials

Figure 43 DuPont: Segmental Revenue

Figure 44 DuPont: Geographical Revenue

Figure 45 Takeda Pharmaceutical Company Limited: Key Financials

Figure 46 Takeda Pharmaceutical Company Limited: Segmental Revenue

Figure 47 Takeda Pharmaceutical Company Limited: Geographical Revenue

Figure 48 Novartis AG: Key Financials

Figure 49 Novartis AG: Segmental Revenue

Figure 50 Novartis AG: Geographical Revenue